小细胞肺癌手术联合化疗与单纯化疗生存期比较  

A comparative study of survival time of surgery combined with chemotherapy and non-surgical chemotherapy in SCLC

作　　者：李光虎[1] 吴勇[1] 张雄基[1] 崔永生[1] 

机构地区：[1]吉林大学第一医院胸外科,长春130021

出　　处：《中华医学杂志》2010年第31期2212-2214,共3页National Medical Journal of China

摘　　要：目的 小细胞肺癌（SCLC）患者手术联合化疗和单纯化疗的生存期比较.方法 收集1999-2004年吉林大学第一医院胸外科37例SCLC患者,术后用依托泊甘＋顺铂或卡铂方案化疗4～6个疗程.选取37例年龄、分期及肿瘤部位相仿的对照组患者,用依托泊甘＋顺铂或卡铂方案化疗6个疗程.两组分别随访5年,进行生存率比较.结果 手术联合化疗组的1、3、5年总的生存率分别为72.97%、35.13%、21.62%.对照组1、3、5年总的生存率分别为54.05%、13.51%、5.41%.两组Ⅰ期SCLC生存率差异有统计学意义（P=0.01）,Ⅱ和Ⅲ期差异无统计学意义（P=0.06,P=0.836）.结论 手术后联合化疗对Ⅰ期的SCLC具有良好的治疗效果.Objective To compare the survival time of surgery combine with chemotherapy with non-surgery chemotherapy in SCLC.Methods 37 SCLC post operation patients were received 4-6 cycles of chemotherapy of ＂etoposide ＋ cisplatin or carboplatin＂.37 SCLC patients were selected be control group,whose age 、stage and site of tumor were similar to surgery combine with chemotherapy group,and received 6 cycles of chemotherapy of ＂etoposide ＋ cisplatin or carboplatin＂.Two groups were followed up 5 year and compared with the survival time.Results The 1,3,5 year survival rate of surgery combined with chemotherapy group were 72.97%,35.13%,21.62%.The 1,3,5 year survival rate of control group were 54.05%,13.51%,5.41%.The survival rate of stageⅠ（P = 0.01） was significantly different,but stage Ⅱ（P =0.06） and stage Ⅲ （P = 0.836） were no difference between the two group of SCLC.Conclusion It was found that surgery combined with chemotherapy got satisfactory effects in stage Ⅰ SCLC.

关 键 词：癌 小细胞 药物疗法 联合 手术 

分 类 号：R734.2[医药卫生—肿瘤]